Replies to post #226325 on Biotech Values

[dewophile]

Getting high rates of cure in hep B may be a rather long shot altogether but curious why you are bearish on RNAi in particular. Seems to me the ability to lower HBSAg (albeit modestly) w data to date is still much better than you could ever get with a nuke. Seems like at least a step in the right direction to me

[DewDiligence]

VIR IPOs 8.21*M shares @$20.00:

https://www.globenewswire.com/news-release/2019/10/10/1928390/0/en/Vir-Biotechnology-Announces-Pricing-of-Initial-Public-Offering.html

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.

Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

*Assuming exercise of underwriter’s option.